Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue
Primary Purpose
Sjogren's Syndrome
Status
Unknown status
Phase
Phase 4
Locations
Finland
Study Type
Interventional
Intervention
dehydroepiandrosterone
Sponsored by
About this trial
This is an interventional treatment trial for Sjogren's Syndrome focused on measuring Sjögren's syndrome, fatigue, salivary gland, dehydroepiandrosterone
Eligibility Criteria
Inclusion Criteria:
- Primary SS according to the American-European consensus criteria
- General Fatigue ≥14 calculated from MFI-20 (Multiple fatigue inventory-20 questionnaire; the value was based on a pilot study of 239 members of the Finnish SS patient association)
- subnormal serum S-DHEAS values (the reference values were calculated based on a pilot study of 81 healthy women and 57 healthy men).
Exclusion Criteria:
- Age <18 years or >80 years
- prisoner
- individuals not able to give their informed consent
- history of breast cancer
- history of uterus cancer
- history of prostatic cancer
- history of stroke or prothrombotic coagulation disorders
- pregnant or lactating women
- fertile patients without adequate prevention
- difficult acne
- a significant liver disease
- patients with changes in their systemic medication taken for SS during the previous three months 13) patients taking more than 10 mg prednisolone per day
Sites / Locations
- Department of Medicine, Helsinki University Central Hospital
Arms of the Study
Arm 1
Arm Type
Placebo Comparator
Arm Label
2
Arm Description
180 patients divided to two separate groups (each containing 90 patients). This study has a cross-over, wash-out design, which consists of two 4 month treatment period separated by a one month long wash-out period. During one treatment period the patient gets placebo and during one of the treatment periods the patient gets 50mg of dehydroepiandrosterone (DHEA) in the morning.
Outcomes
Primary Outcome Measures
Fatigue
Secondary Outcome Measures
Quality of life
Full Information
NCT ID
NCT00543166
First Posted
October 9, 2007
Last Updated
November 2, 2007
Sponsor
University of Helsinki
Collaborators
Göteborg University, Uppsala University
1. Study Identification
Unique Protocol Identification Number
NCT00543166
Brief Title
Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue
Official Title
Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue
Study Type
Interventional
2. Study Status
Record Verification Date
October 2007
Overall Recruitment Status
Unknown status
Study Start Date
February 2003 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2009 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
University of Helsinki
Collaborators
Göteborg University, Uppsala University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Our research contributes to the understanding of some of the basic biology of the salivary glands. The etiology and many of the pathomechanisms of Sjögren's syndrome are unknown. In particular, reasons for the female dominance, late age of onset, fatigue and the prominent involvement of exocrine glands are unknown. We hypothesize, due to the disease characteristics, that the primary target hit by the disease process is the secretory acinar cell and that this cell is particularly damaged in women due to insufficient support, normally provided by dehydroepiandrosterone and its intracrine processing.
Detailed Description
We hypothesize, due to the Sjögren's syndrome (SS) disease characteristics, that the primary target hit by the disease process is the secretory acinar cell and that this cell is particularly in women damaged due to insufficient support, normally provided by dehydroepiandrosterone and its intracrine processing. Dehydroepiandrosterone deficiency at the time of adrenopause seems to us as the more likely endocrine trigger than estrogen deficiency caused by menopause as androgens in general are considered to be protective against autoimmunity and estrogens to favor it. Acinar cell is normally responsible for the production of primary saliva. Acinar cell damage can lead to acinar cell apoptosis and loss. Normally this is compensated by division of the acinar cells in situ or, according to recent reports, perhaps rather by division and subsequent migration of one of the daughter cells into the acinar space and transdifferentiation of this intercalated ductal cell progenitor into mature acinar cell. In SS this remodeling seems to be impaired, perhaps for the same reason, which also leads to primary acinar cell damage. According to this hypothesis, the primary changes occur in the salivary glands and more specifically in the acinar cells, whereas immune activation and autoimmunity are secondarily activated against abnormally damaged acinar cells so that individuals with the "right" genetic background also produce SS-A and SS-B antibodies. The cause of the acinar cell damage may not be a direct, damaging stimulus, e.g. virus infection or irradiation damage, but rather lack of a supporting anabolic stimulus and inadequate maintenance of the acinar cell health leading to cytopathic acinar cell changes. In peri-menopausal women (who still produce some estrogens) this abnormal antigen release and processing from acinar cells, which reveals cryptic epitopes, together with autoimmunity enhancing effects of estrogens, may lead to the full picture of SS (Cutolo et al., 2004).
This neuroimmunoendocrine working hypothesis would explain many central disease characteristics, but does not provide a final answer to the mystery of this intriguing syndrome as the reasons for the insufficient production and generation of DHEA remain to be solved. We have done some preliminary studies to analyze this topic by mapping the signals of the extracellular matrix in the adrenal cortex, where the cells proliferate in the outer zone and subsequently migrate in a centripetal direction, during which phenotypic transition occurs from the outer zone (zona glomerulosa) cells producing aldosterone to the intermediate zone (zona fasciculata) cells producing glucocorticosteroids and finally to the inner zone (zona reticularis) cells producing DHEA. However, in this research project we have decided to totally focus on the salivary gland acinar cell-sex steroid interactions.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sjogren's Syndrome
Keywords
Sjögren's syndrome, fatigue, salivary gland, dehydroepiandrosterone
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
107 (Actual)
8. Arms, Groups, and Interventions
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
180 patients divided to two separate groups (each containing 90 patients). This study has a cross-over, wash-out design, which consists of two 4 month treatment period separated by a one month long wash-out period. During one treatment period the patient gets placebo and during one of the treatment periods the patient gets 50mg of dehydroepiandrosterone (DHEA) in the morning.
Intervention Type
Drug
Intervention Name(s)
dehydroepiandrosterone
Other Intervention Name(s)
DHEA
Intervention Description
50 mg of dehydroepiandrosterone in the morning for 4 months in the treatment group.
Primary Outcome Measure Information:
Title
Fatigue
Time Frame
prospective
Secondary Outcome Measure Information:
Title
Quality of life
Time Frame
prospective
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Primary SS according to the American-European consensus criteria
General Fatigue ≥14 calculated from MFI-20 (Multiple fatigue inventory-20 questionnaire; the value was based on a pilot study of 239 members of the Finnish SS patient association)
subnormal serum S-DHEAS values (the reference values were calculated based on a pilot study of 81 healthy women and 57 healthy men).
Exclusion Criteria:
Age <18 years or >80 years
prisoner
individuals not able to give their informed consent
history of breast cancer
history of uterus cancer
history of prostatic cancer
history of stroke or prothrombotic coagulation disorders
pregnant or lactating women
fertile patients without adequate prevention
difficult acne
a significant liver disease
patients with changes in their systemic medication taken for SS during the previous three months 13) patients taking more than 10 mg prednisolone per day
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yrjö Konttinen, MD, PhD
Organizational Affiliation
Helsinki University Central Hospital, Helsinki, Finland
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Medicine, Helsinki University Central Hospital
City
Helsinki
ZIP/Postal Code
00029
Country
Finland
12. IPD Sharing Statement
Citations:
PubMed Identifier
15593200
Citation
Laine M, Virtanen I, Salo T, Konttinen YT. Segment-specific but pathologic laminin isoform profiles in human labial salivary glands of patients with Sjogren's syndrome. Arthritis Rheum. 2004 Dec;50(12):3968-73. doi: 10.1002/art.20730.
Results Reference
background
PubMed Identifier
15940770
Citation
Konttinen YT, Tensing EK, Laine M, Porola P, Tornwall J, Hukkanen M. Abnormal distribution of aquaporin-5 in salivary glands in the NOD mouse model for Sjogren's syndrome. J Rheumatol. 2005 Jun;32(6):1071-5.
Results Reference
background
PubMed Identifier
11409117
Citation
Valtysdottir ST, Wide L, Hallgren R. Low serum dehydroepiandrosterone sulfate in women with primary Sjogren's syndrome as an isolated sign of impaired HPA axis function. J Rheumatol. 2001 Jun;28(6):1259-65.
Results Reference
background
PubMed Identifier
17665393
Citation
Laine M, Porola P, Udby L, Kjeldsen L, Cowland JB, Borregaard N, Hietanen J, Stahle M, Pihakari A, Konttinen YT. Low salivary dehydroepiandrosterone and androgen-regulated cysteine-rich secretory protein 3 levels in Sjogren's syndrome. Arthritis Rheum. 2007 Aug;56(8):2575-84. doi: 10.1002/art.22828.
Results Reference
result
PubMed Identifier
20191499
Citation
Virkki LM, Porola P, Forsblad-d'Elia H, Valtysdottir S, Solovieva SA, Konttinen YT. Dehydroepiandrosterone (DHEA) substitution treatment for severe fatigue in DHEA-deficient patients with primary Sjogren's syndrome. Arthritis Care Res (Hoboken). 2010 Jan 15;62(1):118-24. doi: 10.1002/acr.20022.
Results Reference
derived
Learn more about this trial
Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue
We'll reach out to this number within 24 hrs